November 14, 2025

Bitget Partners with Tiger.com, Bringing High-Speed Tools to Intraday Traders Leave a reply Bitget Partners with Tiger.com, Bringing High-Speed Tools to Intraday Traders Bitget Partners with Tiger.com, Bringing High-Speed Tools to Intraday Traders VICTORIA, Seychelles, Nov. 14, 2025 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), has announced a new partnership with Tiger.com, a professional trading terminal built for precision, speed, and strategy. The collaboration allows traders to connect directly to Bitget through Tiger’s platform in seconds, unlocking a seamless environment for intraday trading and advanced market analysis. Tiger.com, chosen by over 300,000 users globally, offers access to cryptocurrencies, stocks, futures, and Forex, making it an all-in-one ecosystem for traders who value performance and adaptability. Its comprehensive interface supports a wide array of technical tools, including customizable Depth of Market views, cluster and trade feeds, advanced charting with more than 60 indicators, and robust risk management modules. The platform also features training simulators and strategy playback tools, giving traders the ability to test, learn, and optimize their performance in real-world conditions. The partnership brings Bitget’s deep liquidity, fast execution, and institutional-grade infrastructure to Tiger’s community, enabling users to execute their strategies with the same level of efficiency used by top professionals. “This partnership is about empowering the trading community with tools that match their ambition,” said Gracy Chen, CEO at Bitget. “Bitget’s liquidity and security, combined with Tiger’s precision trading environment, offer a truly professional-grade experience for active traders. Together, we’re bridging speed, depth, and strategy into one seamless ecosystem.” CEO Tiger.com, “Our goal has always been to give traders a full spectrum of solutions designed to meet their goals of both financial and crypto markets—from asset variety, technical analysis, to execution speed. Partnering with Bitget adds another dimension to that mission, giving our users direct access to one of the world’s most innovative and liquid

Bitget Sees Uptick in VIP Demand for Yield Strategies Leave a reply Bitget Sees Uptick in VIP Demand for Yield Strategies Bitget Sees Uptick in VIP Demand for Yield Strategies VICTORIA, Seychelles, Nov. 14, 2025 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), following the significant rise in demand from VIP clients for advanced yield solutions has announced a limited-time migration package designed to make the transition into yield strategies more efficient. This integrated support system turns the choice to move over into an immediate edge, helping new capital start working from day one. It brings together early-stage advantages such as up to 1,600 BGB in airdrops for capital deployment, 100% bonus interest vouchers paired with exclusive high-yield Earn options, an up to 80 USDT rebate with onchain fees waived, complimentary access to the BG Explorer Pack with priority token distributions, and extra PoolX allocations for upcoming token launches. “Our clients have moved beyond asking if they should adopt yield strategies,” said Gracy Chen, CEO of Bitget. “The conversation has shifted to which combination of our products best positions their portfolio for the liquidity phase ahead. We’re seeing a clear evolution from simple accumulation to proactive capital deployment.” Bitget VIP delivers dedicated account management, deep-liquidity execution, and curated structured-yield and wealth-management solutions tailored to institutional and high-net-worth users. The program is engineered for traders who require clarity, speed, and precision within the UEX framework, a unified model that brings together centralized liquidity, tokenized assets, and onchain tools in a single ecosystem. About Bitget Established in 2018, Bitget is the world’s largest Universal Exchange (UEX), serving over 120 million users with access to millions of crypto tokens, tokenized stocks, ETFs, and other real-world assets, while offering real-time access to Bitcoin price, Ethereum price, XRP price and other cryptocurrency prices, all on a single platform. The ecosystem is committed to helping users trade smarter with its AI-powered trading tools, interoperability across tokens

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Leave a reply INSIDE INFORMATION REGULATED INFORMATION Correction and Replacement Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah’s Chairman and Management, and a convertible bond. This press release replaces the press release issued on November 13, 2025, at 10:11 pm CET / 4:11 pm ET in order to replace and correct the gross proceeds of the private placement and registered direct offering and to add a paragraph under the header “Additional Information” (statutory auditor’s assessment) Mont-Saint-Guibert, Belgium – November 14, 2025, 1:30 am CET / November 13, 7:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA) through neuromodulation, today announced a €17 million private placement of equity, a U.S. $5.6 million registered direct offering, combined with a convertible bond financing of up to €45 million. The private placement consists of the issuance of 4,265,714 new ordinary shares at a subscription price per share of €4.00 (approximately U.S. $4.6304 at current exchange rates) with gross proceeds totaling €17 million (approximately U.S. $20 million at current exchange rates). The closing of the private placement is expected to occur on or about November 17, 2025, subject to customary closing conditions. Degroof Petercam acted as the sole book runner for this private placement. The ordinary shares are being sold in a private placement and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Additionally, the registered

Nyxoah Reports Third Quarter 2025 Financial and Operating Results. Leave a reply REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives initial revenue. Mont-Saint-Guibert, Belgium – November 13, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the third quarter of 2025. Recent Financial and Operating Highlights Completed the first commercial implants of U.S. patients, and generated first U.S. revenue as early as September Reimbursement secured with Medicare and private payers, achieving 100% approval rate on prior authorization submissions from United Healthcare, Blue Cross Blue Shield, and Anthem. In all these approvals, the CPT code 64568 was accepted Revenue for the third quarter of 2025 was €2.0 million, representing 56% year over year growth, compared to €1.3 million in the third quarter of 2024 Cash, cash equivalents and financial assets were €22.5 million on September 30, 2025, compared to €43.0 million at the end of June 30, 2025. “The first weeks post FDA approval have been a huge success. We already completed the first implants in September. The response from physicians has been overwhelmingly positive, driven by the excitement of finally having real optionality in hypoglossal nerve stimulation for OSA patients,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “We also secured reimbursement and generate the first U.S. revenue within the first month post FDA approval. The financing transaction announced today will support our sustained growth in the U.S. market. The momentum and enthusiasm couldn’t be greater.” Strong Initial U.S. Commercial Launch The Company is executing its focused two-pronged launch strategy, targeting